Sermorelin · Safety

Sermorelin side effects

Q: What are the most common sermorelin side effects?

Reactions at the injection site, such as redness, itching, swelling or brief pain, are the effects most consistently reported in the published GHRH studies [1][2]. Headache, flushing, and a feeling of warmth after dosing have also been described. Most reported effects have been mild, and none of that is a promise about your own experience.

Q: Is sermorelin safer than growth hormone therapy?

That comparison is not established, and it should not be assumed. A 2007 systematic review of growth hormone in healthy older adults found that adverse events were more common in the growth hormone groups than in controls [4]. Sermorelin acts upstream and preserves the body's own feedback, which is a mechanistic argument rather than a demonstrated safety advantage. The honest answer is that the two have different evidence bases and both require supervision.

Q: Can sermorelin affect blood sugar?

Growth hormone influences glucose metabolism, so glucose is a reasonable thing for a prescribing physician to keep an eye on, particularly for someone with a history of insulin resistance or diabetes. Discuss any such history during the evaluation rather than after starting.

Q: Who should not take sermorelin?

Sermorelin is not appropriate for people with an active malignancy, for people who are pregnant or breastfeeding, or for people with certain endocrine conditions, and there are other histories that make it unsuitable. This is one of the reasons the evaluation and the baseline panel come before a prescription rather than after it.

Q: What should I do if I have a reaction?

Contact your care team about anything persistent, worsening or unexpected. Swelling of the face or throat, trouble breathing, or hives need urgent attention. In an emergency, call 911. Do not adjust your own dose in response to a side effect; that decision belongs to the prescribing physician.

What the published human studies actually report, what a prescribing physician screens for, and which reactions mean call us rather than wait.

Medically reviewed by the Kesbury Health Clinical Team · Last updated 2026-09-02

Quick answer

The side effects reported most consistently with sermorelin and other GHRH injections are local reactions at the injection site: redness, itching, swelling or brief pain. Headache, flushing and transient warmth after dosing have also been described. In the published human studies of GHRH(1-29) in older adults, treatment was tolerated well enough that participants completed multi-week home dosing protocols [1][2]. That is not the same as saying the medication is risk-free, and it is not a claim about your own experience. Sermorelin is a compounded, physician-prescribed medication that is not appropriate for everyone, which is why the evaluation and the baseline panel come first. Anything persistent, worsening or unexpected is a reason to contact your care team, and airway or facial swelling, trouble breathing or hives need urgent care.

What has been reported in the published studies?

The controlled human data on GHRH(1-29) in older adults is modest in size and consistent in shape. A 1992 study dosed older men twice daily for 14 days at 0.5 mg and 1 mg [1]. A 1997 study had eleven healthy men aged 64 to 76 self-inject 2 mg nightly at home for six weeks [2]. A 2012 controlled trial ran GHRH in adults with mild cognitive impairment and in healthy older adults [3]. Across that literature the effects that recur are local and mild, and the studies were completed rather than halted.

The 2012 trial is also the clearest illustration of what a GHRH signal does to a laboratory marker rather than to a person: treatment with GHRH increased insulin-like growth factor 1 levels by 117% (P < .001) [3]. That is a measured biochemical effect, not a promise about how anyone felt, and it is a reminder that the marker and the experience are different things.

Two caveats travel with those studies. Both are modest in size, and both were run in selected populations under supervision. Neither supports a general claim that sermorelin is safe for anyone who wants it.

How does this compare with growth hormone therapy?

This is the comparison most people are actually asking about, and the honest answer is less flattering than the marketing version. A 2007 systematic review in Annals of Internal Medicine pooled the growth hormone trials in healthy elderly participants: 220 participants received growth hormone across 107 person-years, and the review reported that adverse events, including soft tissue edema, joint pain, carpal tunnel syndrome and gynecomastia, were more common in the growth hormone groups than in controls [4].

Sermorelin is a different medication acting one step upstream, and the mechanistic argument is that preserving pituitary feedback limits the size of the signal. That argument is reasonable. It is not the same as a head-to-head safety trial, and no such trial establishes sermorelin as safer. Treat anyone who tells you otherwise as overselling.

What does a physician screen for before prescribing?

History that rules therapy out, including active malignancy, pregnancy or breastfeeding, and certain endocrine conditions.
Glucose and metabolic history, because growth hormone influences glucose handling.
Baseline IGF-1, which gives a reference point for dosing and for later monitoring [5].
Current medications, including anything affecting the endocrine axis.
What you are actually trying to fix, because a symptom with a treatable cause deserves the workup for that cause first.

What to watch for once you start

Local site reactions that stay local and settle within a day or two are the common pattern. What deserves a message to your care team is anything that persists, spreads, or is new and unexplained: joint pain or stiffness, swelling in the hands or ankles, numbness or tingling in the hands, changes in vision, or a change in how you tolerate carbohydrate. What deserves urgent care is facial or throat swelling, difficulty breathing, or hives. In an emergency, call 911.

The honest framing

Sermorelin is a prescription medication with a real, if modest, human evidence base and a real requirement for supervision. Reported effects have been mostly mild and mostly local. No medication is risk-free, this one is not appropriate for everyone, and individual results vary. A provider that answers "are there side effects" with "none" is not describing a medication.

How physician-directed sermorelin works at Kesbury Health

Complete a short online assessment about your goals, symptoms and health history. It takes about 60 seconds to begin.
A licensed Kesbury Health physician reviews what you submitted and decides whether therapy is a reasonable fit for you, or whether something else should be looked at first.
Baseline labs where they apply. The $179 Sermorelin Baseline Panel is a prerequisite for sermorelin therapy, and the results can end the conversation rather than continue it.
If therapy is appropriate, the medication is compounded by a licensed U.S. pharmacy and shipped to your door, with dosing set to you rather than to a chart.
Ongoing physician oversight adjusts the protocol over time, with a 90-day re-evaluation built into the sermorelin program.

Care is delivered by telehealth to residents of the ten states where your Kesbury Health physician is licensed: Alabama, District of Columbia, Delaware, Florida, Maryland, Michigan, New Jersey, Ohio, Pennsylvania and Texas. Eligibility is confirmed during the assessment.

Frequently asked questions

What are the most common sermorelin side effects?

Reactions at the injection site, such as redness, itching, swelling or brief pain, are the effects most consistently reported in the published GHRH studies [1][2]. Headache, flushing, and a feeling of warmth after dosing have also been described. Most reported effects have been mild, and none of that is a promise about your own experience.

Is sermorelin safer than growth hormone therapy?

That comparison is not established, and it should not be assumed. A 2007 systematic review of growth hormone in healthy older adults found that adverse events were more common in the growth hormone groups than in controls [4]. Sermorelin acts upstream and preserves the body's own feedback, which is a mechanistic argument rather than a demonstrated safety advantage. The honest answer is that the two have different evidence bases and both require supervision.

Can sermorelin affect blood sugar?

Growth hormone influences glucose metabolism, so glucose is a reasonable thing for a prescribing physician to keep an eye on, particularly for someone with a history of insulin resistance or diabetes. Discuss any such history during the evaluation rather than after starting.

Who should not take sermorelin?

Sermorelin is not appropriate for people with an active malignancy, for people who are pregnant or breastfeeding, or for people with certain endocrine conditions, and there are other histories that make it unsuitable. This is one of the reasons the evaluation and the baseline panel come before a prescription rather than after it.

What should I do if I have a reaction?

Contact your care team about anything persistent, worsening or unexpected. Swelling of the face or throat, trouble breathing, or hives need urgent attention. In an emergency, call 911. Do not adjust your own dose in response to a side effect; that decision belongs to the prescribing physician.

Ask the safety questions before you start

Take the free 60-second Kesbury Health assessment. A licensed physician reviews your history and the baseline panel, and the answer can be that sermorelin is not the right fit for you.

Start your free 60-second assessment →

Kesbury Health is a LegitScript-certified (#51875982) telehealth longevity practice licensed in ten states. Sermorelin and NAD+ are compounded medications prescribed by a licensed physician after review. Compounded medications are not FDA-approved. This page is educational and is not individualized medical advice. Statements on this page have not been evaluated by the FDA. Individual results vary.

References (primary sources)

Every reference below was checked against its PubMed record on 2026-09-02. Links open the abstract.

Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology and Metabolism. 1992;75(2):530-535. doi:10.1210/jcem.75.2.1379256. PMID 1379256.
Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. doi:10.1016/s0026-0495(97)90174-8. PMID 9005976.
Baker LD, Barsness SM, Borson S, Merriam GR, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology. 2012;69(11):1420-1429. doi:10.1001/archneurol.2012.1970. PMID 22869065.
Liu H, Bravata DM, Olkin I, Nayak S, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine. 2007;146(2):104-115. doi:10.7326/0003-4819-146-2-200701160-00005. PMID 17227934.
Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clinical Chemistry. 2011;57(4):555-559. doi:10.1373/clinchem.2010.150631. PMID 21285256.

Keep reading